Cytek Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cytek Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and its Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
加利福尼亞州弗裏蒙特，2025年1月2日（全球新聞網）-- Cytek生物科學公司（納斯達克：CTKB），一家領先的電芯分析解決方案公司，今天宣佈公司將參加即將在加利福尼亞州舊金山舉行的第43屆年度摩根大通醫療大會。
Cytek management is scheduled to present on Thursday, January 16th at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com.
賽泰克管理層計劃於1月16日（星期四）太平洋時間上午8:15 / 東部時間上午11:15進行演講。相關方可以通過公司網站的「投資者」部分訪問該演講的現場直播和歸檔網絡廣播：investors.cytekbio.com。
About Cytek Biosciences, Inc.
關於Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and its Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .
賽泰克生物科學公司（納斯達克：CTKB）是一家領先的電芯分析解決方案公司，通過提供高分辨率、高含量和高靈敏度的電芯分析，推動下一代電芯分析工具的發展，利用其專利的全光譜分析（FSP）科技。賽泰克獨特的方法利用熒光信號整個光譜中的信息，實現精確和敏感的更高水平的多重分析。賽泰克的平台包括其核心FSP儀器，賽泰克Aurora和Northern Lights系統以及其賽泰克Aurora CS電芯分選機；賽泰克Orion試劑混合物製備系統；增強小顆粒（ESP）檢測技術；以及在Amnis和Guava品牌下的流式細胞儀和成像產品；還提供試劑、軟體和服務，爲客戶提供全面和綜合的解決方案。賽泰克總部位於加利福尼亞州弗裏蒙特，業務覆蓋全球各地。有關公司及其產品的更多信息，請訪問。
Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek的產品僅供研究使用，不得用於診斷程序（除Cytek的Northern Lights-CLC系統和某些試劑外，這些試劑在中國和歐盟可用於臨牀）。
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Enhanced Small Particle, ESP, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
Cytek、全光譜分析、FSP、Cytek Aurora、Northern Lights、Cytek Orion、增強型小顆粒、ESP、Amnis和Guava是Cytek Biosciences, Inc.的商標。
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
除了向證券交易委員會（SEC）提交的文件、新聞稿、公開電話會議和網絡廣播外，Cytek還通過其網站（）、LinkedIn頁面和X（前身爲Twitter）賬戶作爲傳播公司、產品、計劃財務和其他公告、即將舉行的投資者和行業會議的出席情況以及其他事項的信息渠道。這些信息可能被視爲重要信息，Cytek可能會利用這些渠道履行其在《FD規定》下的披露義務。因此，投資者應除了關注Cytek的SEC文件、新聞稿、公開電話會議和網絡廣播外，還應監控Cytek的網站、LinkedIn頁面和X賬戶。
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
媒體聯繫人：
斯蒂芬妮·奧爾森
拉格斯與合夥人
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
投資者聯繫人：
保羅·古德森
投資者關係負責人
Cytek生物科學
pgoodson@cytekbio.com
Source: Cytek Biosciences, Inc.
來源: Cytek Biosciences, Inc.
